Skip to main content

Table 5 Comorbidity in the studied population-based sample and the asthmatics

From: Factors related to under-diagnosis and under-treatment of childhood asthma in metropolitan France

 

Entire sample N = 7,781

Asthmatics N = 903

Undiagnosed Asthma N = 377

Diagnosed Asthma N = 526

Diagnosed Asthma

p-value§

     

Untreated N = 76

Treated N = 353

 

Lifetime eczema, N (%)

1,715 (25.22)

359 (41.65)

121 (33.43)

238 (47.60)

27

(36.00)

175 (52.24)

0.0110

Lifetime allergic rhinitis, N (%)

1,998 (29.28)

537 (61.72)

196 (54.44)

341 (66.86)

41(55.41)

242 (70.76)

0.0102

Severe health problem, N (%)

287 (4.28)

52 (6.30)

17 (5.04)

34 (7.16)

5

(6.85)

23 (7.12)

 

SPT + to indoor allergens, N (%)

1,409 (20.95)

342 (45.60)

119 (37.07)

223 (51.98)

20

167

<0.0001

     

(30.30)

(60.29)

 

SPT + to outdoor allergens, N (%)

824 (12.25)

184 (24.53)

56 (17.45)

128 (29.84)

12

95

0.0111

     

(18.18)

(34.30)

 

SPT + to food allergens, N (%)

138 (2.05)

60 (4.00)

6 (1.87)

24 (5.59)

2 (3.03)

  

BRH10, N (%)

610 (8.95)

140 (17.95)

55 (16.72)

85 (18.85)

6 (8.82)

69 (23.31)

0.0077

BRH15, N (%)

227 (3.33)

85 (10.90)

28 (8.51)

57 (12.64)

2 (2.94)

50 (16.89)

0.0030

  1. HBR10, bronchial hyperactivity to effort with respiratory function decreasing of 10%; HBR15, bronchial hyperactivity to effort with respiratory function decreasing of 15%; SPT +, skin prick test positivity; N, number; NS, not significant;%, percentage.
  2. (&), p-value between asthmatics and the rest of the population.
  3. (^), p-value between diagnosed and undiagnosed asthma.
  4. (§); p-value between treated and untreated asthma.
  5. *, p < 0.05.